Alexandros Makriyannis (born September 9, 1939) is an American biochemist and professor of chemistry and chemical biology in the department of medicinal chemistry at Northeastern UniversityinBoston, Massachusetts, where he directs the Center for Drug Discovery and holds the George Behrakis Chair of Pharmaceutical Biotechnology.[1] His research has focused on the biochemical basis of the endocannabinoid system and on the development of synthetic cannabinoids.
Makriyannis studied chemistry at the University of Cairo.[2] He then earned his Ph.D. in medicinal chemistry at the University of Kansas and went on to research synthetic organic chemistry at the University of California, Berkeley. He worked at Smith, Kline & French Laboratories and Tufts Medical School and then at the University of Connecticut, where he was later appointed Distinguished Professor of Medicinal Chemistry and Professor of Molecular and Cell Biology and Pharmacology.[3][4] He moved to Northeastern University in 2005.[4]
Makriyannis is director of the Center for Drug Discovery at Northeastern University, which he founded in 2005.[3] His work has identified the structure of cannabinoid receptors in the brain, helping to elucidate the psychoactive properties of some of these substances[5][6] and to point towards modifications in the receptors so as to retain the positive effects of cannabinoids while eliminating the negative ones.[7] These studies have informed the development by Makriyannis and his collaborators of synthetic compounds with a view to their use as cannabinergic probes or as medications in drug addiction[8] and in obesity and metabolic disorders.[4] A more recent research interest has been the study of drug interactions with protein targets in membranes.[4] His research has been reported in over 470 publications and his group has filed more than 40 patents.[3]
Subsequent novel inventions include:
2008 “Heteroaryl Urea Compunds as Endocannablnold enzyme Deactivators and a Method of Their Evaluation” – A. Makriyannis, L. Pandarinathan, N. Zvonok, T. Pakkari, L. Chapman
2011 “Method of Developing Cannablnoids with Controlled Duration of Action and Uses Thereof” – A. Makriyannis, G.A Thakur, R. Sharma
2011 “Cannabinergic Resorcinol Analogs” – A. Makriyannis, S. Bajaj, M.R D’Souza, S. Nikas, G. Thakur
2012 “Novel Cannabinerglc Nitrate Esters and Related Analogs” – A. Makriyannis, V.K. Vemuri
2014 Novel urea and carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and their uses thereof” – A. Makriyannis, V.G. Shukla, S.O. Alapafuja
2014 “N·Acylethanolamlne Hydrolyzing Acid Amldase (NAAA) Inhibitors and Their Use Thereof” – A. Makriyannis, M. Malamas, K.V Subramanian, K. Whitten, N. Zvonok, J.M West, S. Pavlopoulos
2017 “Carbarnates ABHD6 and dual ABHD6/MGL Inhibitors and their use thereof”- A. Makriyannis, M. Malamas, M. Lamani, S.I Farah
Makriyannis has founded two biotechnology startups in Burlington, MA dedicated to bringing new and innovative drugs to the market place for human diseases that can be modulated by the endocannabinoid system: